A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Manish R SharmaSmita S JoshiTheodore G KarrisonKenisha AllenGrace SuhRobert MarshMark F KozloffBlasé N PoliteDaniel V T CatenacciHedy L KindlerPublished in: Cancer (2019)
On the basis of our prespecified criteria, tolerability of UGT1A1 genotype-guided mFOLFIRINOX was not established in pancreatic and biliary tract cancers. However, this regimen was effective.